Gland Pharma, a generic injectable pharmaceutical products company, is planning to invest Rs 1,000 crore in the next two to three years to enlarge its product portfolio, expand its capacity, and for R&D spend.
With this in mind, the company plans to invest in a new manufacturing unit at Pashamylaram, near Hyderabad, in addition to its existing three facilities in the state.
Besides, the company will also raise its manufacturing capacity to 250 million injectable units in the next 18 months, from the present 150 million units.
Gland Pharma develops and manufactures generic injectables primarily for the US market, India and other semi-regulated markets.